Ilyas Sahin, Medical Oncologist at Massachusetts General Hospital, shared on X:
“Two FDA approvals in hematologic malignancies today:
1. FDA approved the first all oral HMA + venetoclax regimen (decitabine/cedazuridine + venetoclax) for newly diagnosed AML patients unfit for intensive chemotherapy.
2. FDA also granted accelerated approval to sonrotoclax, a next-generation BCL2 inhibitor, for relapsed/refractory mantle cell lymphoma after ≥2 prior lines including a BTK inhibitor.”
Other articles about FDA Approvals on OncoDaily.